Development direction of Hainan Zhonghe Pharmaceutical Co., Ltd.

As a leader in the industrialization of polypeptide technology in China, Zhonghe Pharmaceutical has always taken the research and development and production of polypeptide drugs as its core development direction and has strong product research and development strength. Following the first successful research and development in China, He Xin&; Reg (thymopentin for injection) 1mg, 10mg, which is the first one listed in China. After the listing of 3mg, 0.25mg of reg (somatostatin for injection) and 0.6 mg of Ri® (thymosin α1)/kloc-0, Zhonghe Pharmaceutical Company introduced He Xin&; Reg "pre-loaded thymopentin injection"; In June, 2006, desmopressin acetate Injection, which does not contain trichlorotert-butanol, was launched in China. New varieties and specifications for subsequent research and development are being introduced one after another. In addition, the Institute of Neutralizing Polypeptide Drugs is developing and applying for more than a dozen kinds of polypeptide drugs, including four new drugs of Class I, two new drugs of Class II and six new drugs of Class III. The research and development of these new drugs will provide strong support for the sustainable development of Zhonghe Pharmaceutical.